# A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

> **NCT04548999** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 769 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Ocrelizumab
- **DRUG:** Antihistamine
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT04548999
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-03
- **Primary completion:** 2025-06-30
- **Final completion:** 2027-09-08
- **Target enrollment:** 769 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548999, "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04548999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*